By repositioning through an epigenetic target, alprazolam was found to interact with the “Other” category target DNAH1 (Q9P2D7), which is related to indications such as Pick’s disease and nasopharyngeal carcinoma. This evidence concerns the gene DNAH1 and nasopharyngeal carcinoma.